SAN FRANCISCO, June 29, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension, announced the receipt of a TECP supplement to its Phase II grant from the National Science Foundation (NSF). The supplement will support in vivo imaging studies of its hydrogels as potential drug carriers for treatment of inner ear disorders.
The objectives of the study are to first determine the residence times and biodegradation rates of the company's Tetra-PEG hydrogel drug delivery system in the middle ear. Once these parameters are established, drugs or drug surrogates will be attached to the hydrogels via ProLynx's b-eliminative linkers, and drug release rates in the middle ear will be determined. Finally, drug-releasing hydrogels will be tested for efficacy in delivering therapeutics to the inner ear.
"We fully expect our hydrogel drug delivery system to be successful in extended delivery of drugs to the middle and inner ear," said Daniel Santi, co-founder and President of ProLynx. "The application is a variation of the technology platform that has been successful in other areas, and this funding will support obtaining proof of concept for this new use."
About ProLynx LLC
ProLynx LLC is a privately held biotechnology company developing proprietary drug delivery systems (DDS) for half-life extension of proteins, peptides and small molecules. The company is seeking to apply its DDS to extend half-lives of drugs and drug candidates of pharmaceutical and biotechnology companies. ProLynx is also seeking to out-license the long lasting drug conjugates in its pre-clinical product portfolio. The company is located in San Francisco, CA. Further information about the company and its capabilities may be found online at http://www.prolynxllc.com.